This Biotech Stock Could Cure Your Portfolio's Pain

Arcutis already has its key drug approved for various diseases and concentrations. Sales are expanding rapidly, and Arcutis is positioned for growth.

The Motley Fool • an hour ago

What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now?

Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 10, 2025

Arcutis Biotherapeutics: The Earnings Inflection Has Arrived

Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's $1.69B estimate, supporting a bullish outlook. ARQT's Q3 net income reached $7.4M, with cash flow break-even now expected in Q4, de-risking the investment case.

Seeking Alpha • Dec 8, 2025

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

Arcutis today announced that Amit Munshi has been appointed to its BOD, and announced the retirement of founder and Board member Bhaskar Chaudhuri, PhD.

GlobeNewsWire • Dec 8, 2025

Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock?

Investors need to pay close attention to ARQT stock based on the movements in the options market lately.

Zacks Investment Research • Dec 2, 2025

Why Shares in Arcutis Biotherapeutics Surged Again This Week

Arcutis aims to expand its market reach with new approvals. Management recently pleased the market with its sales guidance for Zoryve.

The Motley Fool • Nov 21, 2025

Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?

Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Nov 20, 2025

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

GlobeNewsWire • Nov 17, 2025

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Zacks Investment Research • Nov 17, 2025

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with an overweight to biotechnology and an underweight to medtech added the most value relative to the Index. Security selection within medtech, life sciences tools & services, and pharmaceuticals detracted from relative results during the period.

Seeking Alpha • Nov 16, 2025